Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Good Management Practices of Cyclotron Based Gallium-68 Radiopharmaceuticals

Good Management Practices of Cyclotron Based Gallium-68 Radiopharmaceuticals

Iaea

Paperback

Series: IAEA Tecdoc

Technology & EngineeringPhysics

PREORDER - Expected ship date November 30, 2026

ISBN10: 9201051263
ISBN13: 9789201051264
Publisher: International Atomic Energy Agency
Published: Nov 30 2026
Pages: 190
Language: English
Theranostic radiopharmaceuticals deliver radioactive isotopes to targeted tissues, enabling accurate tumour imaging and effective cancer treatment. Interest in these pharmaceuticals has grown significantly over the past decade, with positron-emitting radionuclides such as Gallium-68 (68Ga) increasingly used for personalised diagnosis and therapy monitoring. To support international efforts in this field, the International Atomic Energy Agency (IAEA) launched the coordinated research project (CRP) Production of Cyclotron Based Gallium-68 Radioisotope and Related Radiopharmaceuticals (F22073), in 2020. The CRP facilitated the increased availability of high-quality 68Ga for radiolabelling by promoting the exchange of expertise on cyclotron-based production using the 68Zn(p, n)68Ga route. It also addressed radiopharmaceutical production, quality control, quality assurance, and regulatory considerations for clinical applications. This TECDOC presents contributions from experts and key outcomes of the CRP.

Also from

Iaea

View All

Also in

Physics

View All